Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo, Pankil K. Shah, Natacha Bordry, Robert D. Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre Yves Dietrich, Barbara S. Taylor, Pierre Francois Simand, Darpan Patel, Jing Wang, Intidhar Labidi-Galy, Sara Fertani, Robin J. Leach, Jose Sandoval, Ruben Mesa, Kate Lathrop, Nicolas Mach, Dimpy P. Shah

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

Original languageEnglish (US)
Pages (from-to)1091-1098.e2
JournalCancer Cell
Volume39
Issue number8
DOIs
StatePublished - Aug 9 2021

Keywords

  • COVID-19
  • anti-cancer treatment
  • antibody
  • immune response
  • malignancy
  • oncology
  • pandemic
  • seroconversion
  • tumor
  • vaccine

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer'. Together they form a unique fingerprint.

Cite this